ArticleCureus2025
Late Diagnosis of Pregnancy in a Transmasculine Patient on Testosterone: A Case Report and Patient Perspective.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testosterone therapy can be an important component of care for transgender and gender-diverse (TGD) patients assigned female at birth (AFAB) who wish to pursue hormonal transition. While testosterone often leads to menstrual suppression, it is not a reliable source of contraception and can be teratogenic. Our patient presented to the clinic at age 18 to establish care and resume gender-affirming hormone therapy with testosterone (GAHT-T). The patient's first visit, typically a comprehensive intake conducted to understand patients' general health and transition-related goals, which includes discussion surrounding sexual health and family planning, was truncated due to time constraints. However, a joint decision was made to restart GAHT-T given its importance for the patient's health and transition. Routine labs to assess hormone levels were conducted at follow-up and incidentally showed rising estradiol levels, which are unusual for patients on GAHT-T, and triggered concern and evaluation for a possible underlying endocrine tumor. The patient was ultimately determined to have a single intrauterine pregnancy at 35 weeks of gestation. Understanding patients' comprehensive health and transition-related goals and routinely engaging in shared decision-making can optimize options, autonomy, well-being, and health outcomes for TGD patients. Providers should be skilled in sensitively and meaningfully engaging patients in conversations surrounding overall health, sexual health, contraception counseling, family planning, fertility preservation, and options when there is a late diagnosis of pregnancy. Our patient shares insight on the physical and psychological impact of their journey and the significance of open and safe patient-provider relationships in supporting whole health for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.